The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts
- Conditions
- Saphenous Vein Graft DiseaseMyocardial IschemiaEmbolism
- Registration Number
- NCT00453518
- Lead Sponsor
- Lumen Biomedical
- Brief Summary
This is a multicenter, prospective study designed to demonstrate the performance and safety of the FiberNet Embolic Protection System when used as an adjunctive device during saphenous vein graft (SVG) intervention.
- Detailed Description
The study will involve up to 30 patients to be enrolled using the FiberNet device during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 10 Investigative Sites. The study is a prospective multi-center registry with sequential enrollment of qualified patients who consent to participate and meet all entrance criteria.
The Lumen Biomedical, Inc. FiberNet® Embolic Protection System is indicated for use as a guide wire and embolic protection system to capture and remove embolic material (thrombus/debris) produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts with reference vessel diameters of 1.75 mm to 7.0 mm.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 29
-
Candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting and emergent coronary artery bypass graft (CABG).
-
Myocardial ischemia as evidenced by one or more of the following:
- Diagnosis of stable or unstable angina pectoris
- ECG changes consistent with ischemia
- Positive functional study
- Recent myocardial infarction
-
Lesion(s) is located within SVG and is ≥ 50% and < 100% stenosed.
Clinical Criteria:
- Myocardial infarction with documented total CK-MB > 2 times the upper limit of normal within the past 24 hours, or currently experiencing an acute myocardial infarction.
- Undergone cardiac surgery within the past 60 days.
- A planned invasive surgical procedure within 30 days.
- The lesion(s) is in an SVG that is less than 2 months post-implant.
- Left ventricular ejection fraction < 20%.
- A stroke or transient ischemic neurological attack (TIA) within the past 2 months.
Angiographic Criteria:
- The lesion(s) is in an arterial conduit.
- Lesion is within 10 mm of the proximal anastomosis.
- More than two native lesions [in addition to the SVG lesion(s)] that need to be treated at the index procedure.
- More than two SVGs that need to be treated at the index procedure.
- Chronic total occlusion of a target lesion.
- The SVG lesion(s) requires treatment with a large device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, rheolytic thrombectomy or brachytherapy).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method The primary objective of the study is to evaluate the safety and performance of the FiberNet Embolic Protection System. The primary endpoint is major adverse cardiac events (MACE) rate at 30 days. 30 days
- Secondary Outcome Measures
Name Time Method The secondary study objectives are endpoints related to the use of the FiberNet system and additional safety endpoints. index hospitalization
Trial Locations
- Locations (6)
Christ Hospital
🇺🇸Cincinnati, Ohio, United States
St. Vincent Hospital
🇺🇸Indianapolis, Indiana, United States
William Beaumont Hospital
🇺🇸Royal Oak, Michigan, United States
Lehigh Valley Hospital
🇺🇸Allentown, Pennsylvania, United States
Riverside Methodist Hospital
🇺🇸Columbus, Ohio, United States
Munroe Regional Medical Center
🇺🇸Ocala, Florida, United States